Neurocrine Biosciences (NBIX) Tops Q3 EPS by 58c
Tweet
Share
E-mail
Get Alerts NBIX Hot Sheet
Price: $149.05 -1.83%
Revenue Growth %: +30.8%
Financial Fact:
Deferred gain on real estate: 853K
Today's EPS Names:
VIVO, OCCI, ALZN, More
Revenue Growth %: +30.8%
Financial Fact:
Deferred gain on real estate: 853K
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Neurocrine Biosciences (NASDAQ: NBIX) reported Q3 EPS of $2.17, $0.58 better than the analyst estimate of $1.59. Revenue for the quarter came in at $794.9 million versus the consensus estimate of $748.62 million.
For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Freedom Broker Downgrades Nucor (NUE) to Hold, 'Guides Conservative Earnings Yet Again'
- CCB Int'l Starts Neurocrine Bio. (NBIX) at Outperform
- Corpay agrees to $100M FTC settlement over marketing practices
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
